The agency published a final rule that transitions insulin and other products from regulation as a drug to a biologic.
In patients with Parkinson’s disease, dementia, and neuropathy, higher out-of-pocket drug prices were associated with lower adherence for common...
The complement C5 inhibitor had a similar magnitude of clinical effect as that seen in eculizumab studies.
The Food and Drug Administration advised health care professionals to stop prescribing and dispensing lorcaserin and to contact patients who are...
A network meta-analysis of pharmacologic prophylaxis shows little evidence for efficacy in children.
SAN DIEGO – “The time has come to move past using a one-size-fits-all approach to assess the fifth vital sign,” Dr. Bonakdar said.
The FDA began testing samples of metformin for the carcinogen NDMA at the end of last year.